ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS INC (ALXO): 5 pipeline candidates · 1 upcoming catalyst · ~22 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
22.0 months
D/E 0.18 · 0% dilution
Lead: Phase 2
5 candidates
1 upcoming, next in ~204d
1 buy · 4 sells (180d)
A transparent, data-derived signal for ALX ONCOLOGY HOLDINGS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$194.4M
Cash
$32.4M
Quarterly Burn
$18.6M
Runway
22.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| ALTA-002 | Preclinical |
| ALX2004 | Phase 1 |
| eribulin | Phase 2 |
| evorpacept | Phase 2 |
| vinorelbine | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
65
Total value held
$114.6M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 13,011,849 | $26.1M |
| vanguard capital management llc | 8,359,472 | $16.8M |
| blackstone inc. | 5,826,544 | $11.7M |
| driehaus capital management llc | 5,734,620 | $11.5M |
| marshall wace, llp | 3,757,216 | $7.5M |
| 5am venture management, llc | 3,057,325 | $6.1M |
| orbimed advisors llc | 2,866,256 | $5.7M |
| adage capital partners gp, l.l.c. | 2,000,000 | $4.0M |
| millennium management llc | 1,988,559 | $4.0M |
| two sigma investments, lp | 1,587,833 | $3.2M |
Showing top 10 of 65 institutional holders of ALX ONCOLOGY HOLDINGS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ALX ONCOLOGY HOLDINGS INC's pipeline?
ALX ONCOLOGY HOLDINGS INC (ALXO) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ALX ONCOLOGY HOLDINGS INC's lead drug candidate?
ALX ONCOLOGY HOLDINGS INC's most advanced tracked candidate is ALTA-002 (Preclinical) for Oncology — to promote innate and adaptive anti-cancer immune responses targeted to myeloid cells in the tumor.
What is ALX ONCOLOGY HOLDINGS INC's next catalyst?
ALX ONCOLOGY HOLDINGS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: HALAVEN" — expected January 8, 2027.
What is ALX ONCOLOGY HOLDINGS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ALX ONCOLOGY HOLDINGS INC has approximately 22.0 months of cash runway.
What is ALX ONCOLOGY HOLDINGS INC's market capitalization?
ALX ONCOLOGY HOLDINGS INC's market capitalization is approximately $194.4M.
Get the full picture on ALX ONCOLOGY HOLDINGS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.